

## IN THE CLAIMS:

1-54 (Cancelled)

55. (Currently amended) An isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of ~~a TEM protein selected from the group consisting of~~ potassium inwardly-rectifying channel, subfamily J, member 8; ~~vascular cell adhesion molecule 1; NADH:ubiquinone oxidoreductase MLRQ subunit homolog; hypothetical protein MGC5508; syndecan 2 (heparan sulfate proteoglycan 1, cell surface associated, fibroglycan); hypothetical protein BC002942; uncharacterized hematopoietic; stem/progenitor cells protein MDS032; FAT tumor suppressor homolog 1 (Drosophila); G protein-coupled receptor 4; amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease); tumor necrosis factor receptor superfamily, member 25 (translocating chain association membrane protein); major histocompatibility complex, class I, A; degenerative spermatocyte homolog, lipid desaturase (Drosophila); matrix metalloproteinase 25; prostate stem cell antigen; melanoma cell; adhesion molecule; G protein-coupled receptor; protocadherin beta 9; matrix; metalloproteinase 14 (membrane inserted); scotin; chemokine (C-X-C motif) ligand 14; murine retrovirus integration site 1 homolog; integrin, alpha 11; interferon, alpha ; inducible protein (clone IFI-6-16); CLST 11240 protein; H factor (complement) like; tweety homolog 2 (Drosophila); transient receptor potential ; cation channel, subfamily V, member 2; hypothetical protein PRO1855; sprouty homolog 4 (Drosophila); accessory protein BAP31; integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51); gap junction protein, alpha 4, 37kDa (connexin 37); ealsyntenin 1; solute carrier family 26, member 6; family with sequence similarity 3, member C; immunoglobulin heavy constant gamma 3 (G3m marker); hephaestin; hypothetical protein DKFZp761D0211; cisplatin resistance related protein CRP9p; hypothetical protein IMAGE3455200; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE881791; hypothetical protein MGC15523; prostaglandin I2 (prostacyclin) receptor (IP); CD164 antigen; sialomucin; putative G protein-coupled receptor GPCR41; DKFZP566H073 protein; platelet derived growth factor receptor, alpha polypeptide; NADH dehydrogenase~~

~~(ubiquinone) 1 alpha subcomplex, 1, 7.5kDa; CD151 antigen; platelet derived growth factor receptor, beta polypeptide; KIAA0102 gene product; B7 homolog 3; solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane protein band 3-like 1); endothelin receptor type B; defender against cell death 1; transmembrane, prostate androgen induced RNA; Notch homolog 3 (Drosophila); lymphotoxin beta (TNF superfamily, member 3) chondroitin sulfate proteoglycan 4 (melanoma associated); lipoma HMGIC fusion partner; hypothetical protein similar to ankyrin repeat containing protein AKR1; SDR1 short chain dehydrogenase/reductase 1; PCSK7 proprotein convertase subtilisin/kexin type 7; Homo sapiens mRNA, cDNA DKFZp686D0720 (from clone DKFZp686D0720); FAP fibroblast activation protein, alpha; MCAM melanoma cell adhesion molecule; and CRELD1 cysteine rich with EGF-like domains 1.~~

56. (Original) The molecule of claim 55 which is an intact antibody molecule.
57. (Original) The molecule of claim 55 which is a single chain variable region (ScFv).
58. (Original) The molecule of claim 55 which is a humanized antibody.
59. (Original) The molecule of claim 55 which is a human antibody.
60. (Original) The molecule of claim 55 which is bound to a cytotoxic moiety.
61. (Original) The molecule of claim 55 which is bound to a therapeutic moiety.
62. (Original) The molecule of claim 55 which is bound to a detectable moiety.
63. (Original) The molecule of claim 55 which is bound to an anti-tumor agent.
- 64-108. (Canceled)